INVO Bioscience, Inc. (INVO)

NASDAQ: INVO · IEX Real-Time Price · USD
0.780
-0.013 (-1.68%)
Jun 29, 2022 11:54 AM EDT - Market open
-1.68%
Market Cap 9.44M
Revenue (ttm) 3.64M
Net Income (ttm) -6.98M
Shares Out 12.10M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,271
Open 0.760
Previous Close 0.793
Day's Range 0.760 - 0.820
52-Week Range 0.715 - 4.950
Beta -0.38
Analysts Buy
Price Target 2.30 (+194.9%)
Earnings Date Aug 15, 2022

About INVO

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida. [Read more...]

Industry Health Care Equipment & Supplies
Founded 2007
Employees 10
Stock Exchange NASDAQ
Ticker Symbol INVO
Full Company Profile

Financial Performance

In 2021, INVO's revenue was $4.16 million, an increase of 301.06% compared to the previous year's $1.04 million. Losses were -$6.65 million, -20.27% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for INVO stock is "Buy." The 12-month stock price forecast is 2.3, which is an increase of 194.87% from the latest price.

Price Target
$2.3
(194.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

INVO Signs Distribution Agreement with Onesky Holding Limited for Mainland China

Agreement includes minimum purchase obligations upon product registration and approval SARASOTA, Fla. , May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a com...

INVO Bioscience Reports First Quarter 2022 Financial Results

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focus...

INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , May 9, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage f...

INVO Celebrates National Infertility Awareness Week at the INVO Center in Atlanta, Georgia

Bloom Fertility, an INVO Center to grant three eligible patients a full IVC treatment cycle SARASOTA, Fla. , April 28, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage ferti...

INVO Selects Kansas City as additional INVO Center Location

U.S. Market Expansion Continues as Planned SARASOTA, Fla. , April 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on...

INVO Bioscience to Participate in the Lytham Partners Spring 2022 Investor Conference

SARASOTA, Fla. , April 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® m...

INVO Bioscience Reports 2021 Financial Results

Company to Host Conference Call Today at 4:30pm ET; Slide Presentation Also Available SARASOTA, Fla. , March 31, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a co...

INVO Bioscience to Report Fourth Quarter and Fiscal Year 2021 Financial Results on Thursday, March 31, 2022

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stag...

INVO Bioscience to Exhibit at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting

SARASOTA, Fla. , March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell®, an advanced fertility treatment technology which is currently available, is exhibiting ...

INVO Bioscience to Participate in Roundtable Discussion at the 2022 Virtual Growth Conference Presented by Maxim Grou...

SARASOTA, Fla. , March 22, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® ...

New Birmingham INVO Center Offers Families an Affordable Advanced Fertility Treatment Solution to Help Combat Rising ...

SARASOTA, Fla., March 10, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell®, an advanced fertility treatment technology which is currently available through a number...

INVO to Launch Additional INVO Center in Tampa, Florida

SARASOTA, Fla. and TAMPA, Fla.

INVO Bioscience Eyes +20 U.S. Cities To Expand Rollout Of Advanced Infertility Treatment 'INVO Centers'

SAN FRANCISCO, CA / ACCESSWIRE / February 9, 2022 / Today, the global fertility market is a multi-billion industry, yet remains severely underserved, with estimates suggesting more than 90% of couples i...

INVO Bioscience Expands U.S. Commercialization Efforts

SARASOTA, Fla., Feb. 3, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("Company") ("INVO"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide w...

INVO Bioscience Enters into Agreement with Ovoclinic in Spain to Expand INVOcell Commercialization

SARASOTA, Fla. and MADRID, Dec. 16, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell...

INVO Bioscience to Participate in the Lytham Partners Winter 2021 Investor Conference

SARASOTA, Fla., Dec. 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, announce...

INVO Bioscience Obtains Regulatory Approval to Commercialize INVOcell In Thailand

SARASOTA, Fla., Dec. 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, today ann...

Invo BioScience Inc. (INVO) Reports Q3 Loss, Lags Revenue Estimates

Invo BioScience Inc. (INVO) delivered earnings and revenue surprises of -20.00% and -13.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

INVO Bioscience Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update

SARASOTA, Fla., Nov. 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a medical device company focused on creating alternative treatments for patients diagnosed w...

INVO Bioscience to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

SARASOTA, Fla., Nov. 9, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effect...

INVO Bioscience Regains Full U.S. Commercialization Rights

SARASOTA, Fla., Nov. 8, 2021 /PRNewswire/ -- INVO Bioscience, Inc. ("INVO" or the "Company") (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (...

Will Invo BioScience Inc. (INVO) Report Negative Q3 Earnings? What You Should Know

Invo BioScience Inc. (INVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INVO Bioscience Announces Four Individual Poster Abstracts Discussing the Benefits of INVOcell Presented at the 2021 ...

SARASOTA, Fla. and BALTIMORE, Oct. 20, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) , a medical device company focused on commercializing the world's only in vivo Intravaginal Culture Syste...

INVO Bioscience Announces Grand Opening of "Positib Fertility, an INVO Center" in Monterrey, Mexico on November 1, 2021

SARASOTA, Fla. and MONTERREY, Mexico, Oct. 14, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC...

INVO Bioscience Announces $4.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

SARASOTA, Fla., Oct. 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, today ann...